Carotid Stenosis Detected
Screening or symptomatic presentation
All Pathways
Vascular SurgeryManagement
Carotid Artery Stenosis Management (ESVS 2023)
Carotid Artery Stenosis Management (ESVS 2023): Carotid Stenosis Detected → Symptomatic or Asymptomatic? → Symptomatic: Urgent Evaluation → Stenosis Sev...
Pathway Overview
17 steps
Algorithm Steps
17 total
01Start 02Decision Symptomatic or Asymptomatic?
Recent ipsilateral neurological symptoms
- Symptomatic: TIA/stroke in last 6 months referable to territory
- Asymptomatic: incidental finding, contralateral symptoms, or remote event
03Action Symptomatic: Urgent Evaluation
Time-sensitive assessment
- Duplex ultrasound (initial)
- CTA or MRA for confirmation
- Brain imaging (MRI preferred for infarct)
- Cardiology evaluation if indicated
- Treat within 14 days of symptoms (Class I)
04Decision Stenosis Severity
NASCET criteria (measured from ICA)
- <50%: medical therapy
- 50-69%: consider intervention if symptomatic
- 70-99%: intervention recommended if symptomatic
- Near-occlusion/string sign: individual assessment
- Occlusion: no intervention
05Warning Symptomatic 50-99%
Revascularization recommended (Class I)
- CEA or CAS recommended
- Greatest benefit in 70-99% stenosis
- Timing: <14 days from event optimal
- Target perioperative stroke/death <6%
- Medical therapy continues regardless
06Decision CEA vs CAS Decision
Based on individual risk factors
- CEA preferred: age >70, complex plaque, long lesion
- CAS preferred: prior neck surgery/radiation, hostile neck
- CAS: high cardiac risk, contralateral occlusion
- Either: centers with documented low complication rates
07Action Carotid Endarterectomy (CEA)
Gold standard surgical treatment
- Regional or general anesthesia
- Conventional or eversion technique
- Patch closure recommended
- Monitoring: awake or EEG/TCD
- Perioperative aspirin continuation
08Action Post-Procedure Care
Surveillance and secondary prevention
- Blood pressure management (avoid hypotension/hypertension)
- Neurological monitoring (24-48h)
- Duplex surveillance: 1, 6, 12 months then annually
- Continue optimal medical therapy
- Watch for restenosis (>50%)
09Warning Hyperperfusion Syndrome
1-3% risk post-revascularization
- Usually 24h-7 days post-procedure
- Severe headache, seizures, ICH
- More common: severe stenosis, poor collaterals
- Strict BP control: SBP <140 mmHg
- ICU monitoring if high risk
10Action Long-Term Surveillance
Monitor for restenosis and progression
- Annual duplex ultrasound
- Monitor contralateral carotid
- Risk factor control lifelong
- Re-intervention if symptomatic restenosis
- Consider re-intervention for >70% asymptomatic restenosis
11Outcome Stroke Prevention
50-70% relative risk reduction in appropriate patients
12Outcome Ongoing Vascular Risk
Systemic atherosclerosis - cardiac and other vascular events remain risks
13Warning Potential Complications
Know and recognize early
- Stroke/TIA (CEA <3%, CAS slightly higher)
- Myocardial infarction
- Cranial nerve injury (CEA: 5-10%, usually transient)
- Hyperperfusion syndrome
- Hematoma/bleeding
14Action Carotid Artery Stenting (CAS)
Endovascular alternative
- Dual antiplatelet pre-procedure
- Embolic protection device recommended
- Self-expanding stent
- Post-dilation as needed
- Continue DAPT 1-3 months then single antiplatelet
- Path rejoins step 08Shared downstream outcome
- Path rejoins step 13Shared downstream outcome
15Action Asymptomatic 60-99%
CEA may be considered (Class IIa)
- Select patients benefit from CEA
- Life expectancy >5 years
- Low perioperative risk (<3% stroke/death)
- Consider: plaque morphology, stenosis progression
- Optimal medical therapy essential regardless
- Path rejoins step 06Shared downstream outcome
16Action Optimal Medical Therapy
Foundation of all treatment
- Antiplatelet (aspirin or clopidogrel)
- High-intensity statin (LDL <70 mg/dL)
- Blood pressure control
- Diabetes management
- Smoking cessation
- Lifestyle modification
- Path rejoins step 10Shared downstream outcome
- Path rejoins step 16Shared downstream outcome
17Action Asymptomatic: Complete Evaluation
Risk-benefit assessment needed
- Duplex ultrasound
- Confirm stenosis degree with CTA/MRA
- Assess life expectancy (>5 years for benefit)
- Evaluate plaque characteristics (vulnerable features)
- Risk factor assessment
- Path rejoins step 04Shared downstream outcome
Guideline Source
ESVS 2023 Clinical Practice Guidelines on Atherosclerotic Carotid and Vertebral Artery Disease
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Symptomatic patients should be treated within 14 days of symptoms
- CEA vs CAS decision requires individual risk assessment
- High-risk anatomic features may favor CAS or medical therapy
- Perioperative stroke risk must be <6% for symptomatic, <3% for asymptomatic
- Does not cover vertebral artery disease in detail
Applicable Regions
USEUGlobal
EU: ESVS 2023 is current standard
US: AHA/ASA guidelines generally consistent
Version 1Next review: 2027-01-01
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Carotid Artery Stenosis Management (ESVS 2023)?
The Carotid Artery Stenosis Management (ESVS 2023) is a management clinical algorithm for Vascular Surgery. It provides a structured decision tree to guide clinical decision-making, based on ESVS 2023 Clinical Practice Guidelines on Atherosclerotic Carotid and Vertebral Artery Disease.
What guideline is the Carotid Artery Stenosis Management (ESVS 2023) based on?
This algorithm is based on ESVS 2023 Clinical Practice Guidelines on Atherosclerotic Carotid and Vertebral Artery Disease (DOI: 10.1016/j.ejvs.2022.04.011).
What are the limitations of the Carotid Artery Stenosis Management (ESVS 2023)?
Known limitations include: Symptomatic patients should be treated within 14 days of symptoms; CEA vs CAS decision requires individual risk assessment; High-risk anatomic features may favor CAS or medical therapy; Perioperative stroke risk must be <6% for symptomatic, <3% for asymptomatic; Does not cover vertebral artery disease in detail. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Carotid Artery Stenosis Management (ESVS 2023) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free